Our Vaccines

Our Products

Our Products

Our innovative platform technologies provide the capability to proactively create a national reserve of vaccines in a cost-effective and efficient manner unparalleled by our competitors. This has positioned us as a primary partner with the U.S. government for the development of critical anthrax and malaria vaccines.

Pfenex is developing Px563L, a novel anthrax vaccine candidate, in response to the United States government’s unmet demand for increased quantity, stability and dose sparing regimens of anthrax vaccine. The development of Px563L has been funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority, or BARDA, currently funded by a $143.5 million advanced development contract. Additionally, Px563L-SDI, a solid dose formulation of anthrax vaccine, has been funded by the National Institute of Allergy and Infectious Diseases, or NIAID, for up to a total of $22.9 million.

Novel Vaccines

  PRE-CLINICAL PHASE 1 PHASE 2
arrowRight FULLY FUNDED BY THE
US GOVERNMENT
     

Px563L

SDI rPA based Anthrax Vaccine 2nd Generation

Px563L

rPA based Anthrax Vaccine

RPA563

rPA based Anthrax Vaccine

*Development controlled by the US Government

Last Updated: 8/12/16